Can-Fite BioPharma's Phase 2a Study Shows Promising Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: NASDAQ.COM
- Clinical Trial Results: Can-Fite BioPharma's Phase 2a study of Namodenoson in 20 patients with advanced pancreatic ductal adenocarcinoma met its primary safety endpoint, showing promising survival outcomes, particularly with a median overall survival exceeding five months among third-line patients, where 62.5% survived at least five months and 37.5% survived seven months or longer, indicating the drug's potential in heavily pretreated patients.
- Safety and Tolerability: The drug demonstrated good tolerability during the trial, consistent with prior studies, further validating its biological activity; study leader Prof. Salomon Stemmer highlighted the favorable safety profile and prolonged survival, suggesting further investigation in combination with chemotherapy.
- Future Research Directions: Can-Fite plans to advance Namodenoson into a Phase 2b combination study with chemotherapy, supported by preclinical data showing enhanced anti-tumor activity in pancreatic cancer models by blocking multiple growth and drug-resistance pathways, thereby increasing chemosensitivity and justifying the shift towards combination therapy.
- Market Reaction: In the latest trading session, CANF closed at $2.97, up 1.71%, while in pre-market trading, the stock surged to $5.02, reflecting a 76.57% increase, indicating strong market enthusiasm for the clinical trial results.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CANF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CANF
About CANF
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Can-Fite BioPharma Completes Enrollment of 247 Patients in Phase 3 Study
- Clinical Trial Progress: Can-Fite BioPharma has completed enrollment of 247 patients in its pivotal Phase 3 study evaluating the efficacy and safety of Piclidenoson for moderate-to-severe plaque psoriasis, with interim analysis results expected in Q4 2026 or Q1 2027.
- Regulatory Agreement Achieved: The study is conducted under a protocol agreed with both the FDA and EMA, ensuring a clear regulatory pathway for Piclidenoson, indicating the company's compliance and foresight in drug development.
- Drug Characteristics Advantage: Piclidenoson, as a first-in-class oral A3 adenosine receptor agonist, has a unique mechanism of action targeting key inflammatory pathways associated with psoriasis, and has demonstrated a favorable safety profile in over 1,500 subjects, potentially offering a new long-term treatment option for patients.
- Market Potential: The global psoriasis therapeutics market continues to expand, and Can-Fite believes that Piclidenoson's profile as an oral small-molecule therapy addresses the demand for safe, effective, and convenient long-term treatment options, presenting significant commercial value and market prospects.
See More
Can-Fite BioPharma Completes Patient Enrollment for Psoriasis Clinical Trial
- Clinical Trial Enrollment Completed: Can-Fite BioPharma has successfully enrolled 247 patients in its pivotal Phase 3 clinical trial for moderate-to-severe plaque psoriasis, marking a significant milestone, with interim analysis results expected in Q4 2026 or Q1 2027.
- FDA and EMA Agreement: The study is conducted under a protocol agreed with both the FDA and EMA, ensuring a clear regulatory pathway for Piclidenoson, which is anticipated to provide a new oral treatment option for patients, addressing the market's demand for safe and effective long-term therapies.
- Innovative Drug Mechanism: Piclidenoson is a first-in-class oral A3 adenosine receptor agonist with a unique mechanism of action targeting key inflammatory pathways associated with psoriasis, demonstrating a favorable safety profile in over 1,500 subjects tested across clinical studies.
- Significant Market Potential: As the psoriasis therapeutics market continues to expand, Can-Fite believes that Piclidenoson's distinctive profile as an oral small-molecule therapy will effectively meet the urgent needs of patients seeking safe, effective, and convenient long-term treatment options, presenting substantial commercial value.
See More
Stock Futures Dip Ahead of Independence Day as Investors Remain Cautious
- Cautious Market Sentiment: Ahead of America's Independence Day, stock futures are pointing lower as investors remain cautious due to the upcoming June jobs report and ongoing U.S.-Iran diplomatic talks, potentially leading to a softer end to the holiday-shortened week.
- National Beverage Gains: Shares of National Beverage (FIZZ) rose by 6% after announcing a special cash dividend of $3.25 per share, with FY2026 net sales reaching $1.2 billion, gross profit at $437 million with a 37% margin, and EPS of $1.96, reflecting strong innovation momentum and improving market conditions.
- Can-Fite BioPharma Decline: Can-Fite BioPharma (CANF) saw a 12% drop in shares despite reporting positive Phase 2a data for Namodenoson in advanced pancreatic cancer, indicating market skepticism about the drug's future clinical trials despite meeting safety endpoints and showing durable survival rates.
- Embraer Acquisition Impact: Embraer (EMBJ) shares fell by 5% after completing the acquisition of Safran Cabin's remaining 50% stake in the EZ Air Interior joint venture, raising concerns about the financial implications and integration of operations despite gaining full ownership of the cabin interiors production facility.
See More
Biotech Companies See Significant Stock Gains
- Can-Fite Surge: Can-Fite BioPharma Ltd. (CANF) saw its stock soar over 55% to $4.63 following an update on its pancreatic cancer study, where the Phase 2a trial of Namodenoson met primary safety endpoints and showed durable survival outcomes, indicating strong future market potential as the company plans to advance to a Phase 2b combination study with chemotherapy.
- SeaStar Revenue Growth: SeaStar Medical Holding Corp. (ICU) experienced a stock increase of over 30% to $4.86, driven by no specific news, yet its flagship product QUELIMMUNE received FDA approval in 2024, with projected net product revenue of approximately $2 million in 2026, up from $1.2 million in 2025, reflecting strong market demand in critical care treatments.
- Elicio Strategic Refinement: Elicio Therapeutics Inc. (ELTX) jumped over 31% to $5.14, as it was added to the Russell 2000 and 3000 Indexes in 2026, despite its EL-002 product not meeting the primary endpoint in the AMPLIFY-7P trial, the company has refined its Phase 3 development strategy based on trial insights and plans to initiate a Phase 3 trial pending financing, showcasing ongoing R&D progress.
- Regentis European Rollout: Regentis Biomaterials Ltd. (RGNT) rose over 29% to $4.57, with no specific news, but its GelrinC product received CE Mark approval, and the company plans to begin European surgeon training this quarter as part of its commercial rollout preparations, indicating significant market expansion potential in regenerative medicine.
See More
Can-Fite BioPharma Reports Positive Results in Pancreatic Cancer Study
- Patient Enrollment: Can-Fite enrolled 20 patients with advanced pancreatic ductal adenocarcinoma for the Namodenoson study, with eight evaluable patients showing a median survival exceeding five months, indicating the potential efficacy and tolerability of the treatment.
- Significant Treatment Effects: In the Phase IIa study, 14 patients received Namodenoson as a third-line treatment, achieving the main safety goals while demonstrating durable overall survival, suggesting biological activity that warrants further investigation.
- Future Research Plans: Following these promising results, Can-Fite plans to initiate a Phase 2b study combining Namodenoson with chemotherapy, aiming to further validate its effectiveness in treating pancreatic cancer, particularly in patients who have failed standard therapies.
- Positive Market Reaction: Can-Fite's shares surged over 50% after announcing positive early-stage study results, although the stock has fallen approximately 26% this year; however, retail sentiment has turned 'extremely bullish' in the past 24 hours, reflecting confidence in the company's future potential.
See More
Can-Fite BioPharma's Phase 2a Study Shows Promising Results
- Clinical Trial Results: Can-Fite BioPharma's Phase 2a study of Namodenoson in 20 patients with advanced pancreatic ductal adenocarcinoma met its primary safety endpoint, showing promising survival outcomes, particularly with a median overall survival exceeding five months among third-line patients, where 62.5% survived at least five months and 37.5% survived seven months or longer, indicating the drug's potential in heavily pretreated patients.
- Safety and Tolerability: The drug demonstrated good tolerability during the trial, consistent with prior studies, further validating its biological activity; study leader Prof. Salomon Stemmer highlighted the favorable safety profile and prolonged survival, suggesting further investigation in combination with chemotherapy.
- Future Research Directions: Can-Fite plans to advance Namodenoson into a Phase 2b combination study with chemotherapy, supported by preclinical data showing enhanced anti-tumor activity in pancreatic cancer models by blocking multiple growth and drug-resistance pathways, thereby increasing chemosensitivity and justifying the shift towards combination therapy.
- Market Reaction: In the latest trading session, CANF closed at $2.97, up 1.71%, while in pre-market trading, the stock surged to $5.02, reflecting a 76.57% increase, indicating strong market enthusiasm for the clinical trial results.
See More
Can-Fite BioPharma Completes Enrollment of 247 Patients in Phase 3 Study
- Clinical Trial Progress: Can-Fite BioPharma has completed enrollment of 247 patients in its pivotal Phase 3 study evaluating the efficacy and safety of Piclidenoson for moderate-to-severe plaque psoriasis, with interim analysis results expected in Q4 2026 or Q1 2027.
- Regulatory Agreement Achieved: The study is conducted under a protocol agreed with both the FDA and EMA, ensuring a clear regulatory pathway for Piclidenoson, indicating the company's compliance and foresight in drug development.
- Drug Characteristics Advantage: Piclidenoson, as a first-in-class oral A3 adenosine receptor agonist, has a unique mechanism of action targeting key inflammatory pathways associated with psoriasis, and has demonstrated a favorable safety profile in over 1,500 subjects, potentially offering a new long-term treatment option for patients.
- Market Potential: The global psoriasis therapeutics market continues to expand, and Can-Fite believes that Piclidenoson's profile as an oral small-molecule therapy addresses the demand for safe, effective, and convenient long-term treatment options, presenting significant commercial value and market prospects.
See More
Can-Fite BioPharma Completes Patient Enrollment for Psoriasis Clinical Trial
- Clinical Trial Enrollment Completed: Can-Fite BioPharma has successfully enrolled 247 patients in its pivotal Phase 3 clinical trial for moderate-to-severe plaque psoriasis, marking a significant milestone, with interim analysis results expected in Q4 2026 or Q1 2027.
- FDA and EMA Agreement: The study is conducted under a protocol agreed with both the FDA and EMA, ensuring a clear regulatory pathway for Piclidenoson, which is anticipated to provide a new oral treatment option for patients, addressing the market's demand for safe and effective long-term therapies.
- Innovative Drug Mechanism: Piclidenoson is a first-in-class oral A3 adenosine receptor agonist with a unique mechanism of action targeting key inflammatory pathways associated with psoriasis, demonstrating a favorable safety profile in over 1,500 subjects tested across clinical studies.
- Significant Market Potential: As the psoriasis therapeutics market continues to expand, Can-Fite believes that Piclidenoson's distinctive profile as an oral small-molecule therapy will effectively meet the urgent needs of patients seeking safe, effective, and convenient long-term treatment options, presenting substantial commercial value.
See More
Stock Futures Dip Ahead of Independence Day as Investors Remain Cautious
- Cautious Market Sentiment: Ahead of America's Independence Day, stock futures are pointing lower as investors remain cautious due to the upcoming June jobs report and ongoing U.S.-Iran diplomatic talks, potentially leading to a softer end to the holiday-shortened week.
- National Beverage Gains: Shares of National Beverage (FIZZ) rose by 6% after announcing a special cash dividend of $3.25 per share, with FY2026 net sales reaching $1.2 billion, gross profit at $437 million with a 37% margin, and EPS of $1.96, reflecting strong innovation momentum and improving market conditions.
- Can-Fite BioPharma Decline: Can-Fite BioPharma (CANF) saw a 12% drop in shares despite reporting positive Phase 2a data for Namodenoson in advanced pancreatic cancer, indicating market skepticism about the drug's future clinical trials despite meeting safety endpoints and showing durable survival rates.
- Embraer Acquisition Impact: Embraer (EMBJ) shares fell by 5% after completing the acquisition of Safran Cabin's remaining 50% stake in the EZ Air Interior joint venture, raising concerns about the financial implications and integration of operations despite gaining full ownership of the cabin interiors production facility.
See More
Biotech Companies See Significant Stock Gains
- Can-Fite Surge: Can-Fite BioPharma Ltd. (CANF) saw its stock soar over 55% to $4.63 following an update on its pancreatic cancer study, where the Phase 2a trial of Namodenoson met primary safety endpoints and showed durable survival outcomes, indicating strong future market potential as the company plans to advance to a Phase 2b combination study with chemotherapy.
- SeaStar Revenue Growth: SeaStar Medical Holding Corp. (ICU) experienced a stock increase of over 30% to $4.86, driven by no specific news, yet its flagship product QUELIMMUNE received FDA approval in 2024, with projected net product revenue of approximately $2 million in 2026, up from $1.2 million in 2025, reflecting strong market demand in critical care treatments.
- Elicio Strategic Refinement: Elicio Therapeutics Inc. (ELTX) jumped over 31% to $5.14, as it was added to the Russell 2000 and 3000 Indexes in 2026, despite its EL-002 product not meeting the primary endpoint in the AMPLIFY-7P trial, the company has refined its Phase 3 development strategy based on trial insights and plans to initiate a Phase 3 trial pending financing, showcasing ongoing R&D progress.
- Regentis European Rollout: Regentis Biomaterials Ltd. (RGNT) rose over 29% to $4.57, with no specific news, but its GelrinC product received CE Mark approval, and the company plans to begin European surgeon training this quarter as part of its commercial rollout preparations, indicating significant market expansion potential in regenerative medicine.
See More
Can-Fite BioPharma Reports Positive Results in Pancreatic Cancer Study
- Patient Enrollment: Can-Fite enrolled 20 patients with advanced pancreatic ductal adenocarcinoma for the Namodenoson study, with eight evaluable patients showing a median survival exceeding five months, indicating the potential efficacy and tolerability of the treatment.
- Significant Treatment Effects: In the Phase IIa study, 14 patients received Namodenoson as a third-line treatment, achieving the main safety goals while demonstrating durable overall survival, suggesting biological activity that warrants further investigation.
- Future Research Plans: Following these promising results, Can-Fite plans to initiate a Phase 2b study combining Namodenoson with chemotherapy, aiming to further validate its effectiveness in treating pancreatic cancer, particularly in patients who have failed standard therapies.
- Positive Market Reaction: Can-Fite's shares surged over 50% after announcing positive early-stage study results, although the stock has fallen approximately 26% this year; however, retail sentiment has turned 'extremely bullish' in the past 24 hours, reflecting confidence in the company's future potential.
See More
Can-Fite BioPharma's Phase 2a Study Shows Promising Results
- Clinical Trial Results: Can-Fite BioPharma's Phase 2a study of Namodenoson in 20 patients with advanced pancreatic ductal adenocarcinoma met its primary safety endpoint, showing promising survival outcomes, particularly with a median overall survival exceeding five months among third-line patients, where 62.5% survived at least five months and 37.5% survived seven months or longer, indicating the drug's potential in heavily pretreated patients.
- Safety and Tolerability: The drug demonstrated good tolerability during the trial, consistent with prior studies, further validating its biological activity; study leader Prof. Salomon Stemmer highlighted the favorable safety profile and prolonged survival, suggesting further investigation in combination with chemotherapy.
- Future Research Directions: Can-Fite plans to advance Namodenoson into a Phase 2b combination study with chemotherapy, supported by preclinical data showing enhanced anti-tumor activity in pancreatic cancer models by blocking multiple growth and drug-resistance pathways, thereby increasing chemosensitivity and justifying the shift towards combination therapy.
- Market Reaction: In the latest trading session, CANF closed at $2.97, up 1.71%, while in pre-market trading, the stock surged to $5.02, reflecting a 76.57% increase, indicating strong market enthusiasm for the clinical trial results.
See More
